Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.9%

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price traded up 5.9% during trading on Wednesday . The stock traded as high as $124.37 and last traded at $124.01. 550,813 shares were traded during mid-day trading, a decline of 43% from the average session volume of 972,684 shares. The stock had previously closed at $117.12.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Barclays upped their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. BMO Capital Markets assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price objective for the company. Finally, Citigroup upped their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $158.38.

Sarepta Therapeutics Stock Performance

The company has a market cap of $12.09 billion, a price-to-earnings ratio of -21.04 and a beta of 0.94. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock’s fifty day simple moving average is $126.11 and its 200 day simple moving average is $110.47.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same quarter in the prior year, the firm earned ($1.24) EPS. Sarepta Therapeutics’s quarterly revenue was up 53.6% on a year-over-year basis. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

Insider Activity

In other news, Director Stephen Mayo sold 3,135 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares of the company’s stock, valued at approximately $814,118.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Stephen Mayo sold 3,135 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the transaction, the director now owns 6,621 shares of the company’s stock, valued at approximately $814,118.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 in the last 90 days. Company insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after purchasing an additional 41,465 shares in the last quarter. Picton Mahoney Asset Management acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at $2,576,000. WCM Investment Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at $600,000. Capula Management Ltd acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at $1,409,000. Finally, State of New Jersey Common Pension Fund D raised its holdings in shares of Sarepta Therapeutics by 8.2% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company’s stock valued at $4,956,000 after purchasing an additional 3,912 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.